Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H42O4 |
Molecular Weight | 430.62 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@@H](O)C[C@@H](O)[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]6(CC[C@@H](C)CO6)O2
InChI
InChIKey=QMQIQBOGXYYATH-IDABPMKMSA-N
InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1
Ruscogenin is a major steroid sapogenin found in the traditional Chinese medicinal herb Ophiopogon japonicus. It was first isolated from Ruscus aculeatus. Ruscogenin has multiple bioactivities and possesses a variety of pharmacological activities: anti-inflammatory properties, platelet aggregation inhibition, pulmonary hypertension lowering properties, acute lung injury alleviation and other effects. It was shown, that ruscogenin inhibited activation of neutrophil through cPLA2, PAK, Akt, MAPKs, cAMP, and PKA signaling pathways. In addition, Ruscogenin decreased expression of genes involved in hepatic lipogenesis through downregulation of NF-κB-mediated inflammatory responses. It was shown that ruscogenin significantly attenuate LPS-induced acute lung injury (ALI) via inhibiting expressions of TF and iNOS and NF-κB p65 activation, indicating it was a potential therapeutic agent for ALI or sepsis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28933731
Curator's Comment: Known to be CNS penetrant in rats. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map04024 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134424 |
|||
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134424 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24666993
streptozotocin-induced diabetic rat: Two weeks after STZ injection, rats in the treatment group were orally dosed with 0.3, 1.0 or 3.0 mg/kg ruscogenin for 8 weeks. The normal rats were chosen as nondiabetic control group.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26134424
Ruscogenin displayed potent antioxidative effects against Formyl-Met-Leu-Phe (FMLP)-induced extra- and intracellular superoxide generation in mouse bone marrow neutrophils, with IC50 values of 1.07±0.32 μM and 1.77±0.46 μM, respectively. Phorbol myristate acetate (PMA)-elicited extra- and intracellular superoxide generation were also suppressed by ruscogenin, with IC50 values of 1.56±0.46 μM and 1.29±0.49 μM, respectively. However, ruscogenin showed weak inhibition in NaF-induced response. Inhibition of superoxide generation was mediated neither by a superoxide-scavenging ability nor by a cytotoxic effect.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
441893
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
BXI92R2VUJ
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
C012541
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
207-447-2
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
100000078384
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
BXI92R2VUJ
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
SUB15165MIG
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
DTXSID401019319
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | |||
|
35890
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
472-11-7
Created by
admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
|
PRIMARY |
ACTIVE MOIETY